Choosing Alzheimer’s disease prevention clinical trial populations

Joshua D. Grill, Ph.D.1,* and Sarah E. Monsell, M.S.2

1Mary Easton Center for Alzheimer’s Disease Research, Department of Neurology, UCLA, Los Angeles, CA
2National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA

Abstract

To assist investigators in making design choices, we modeled Alzheimer’s disease (AD) prevention clinical trials. We used longitudinal Clinical Dementia Rating Scale Sum of the Boxes data, retention rates, and the proportions of trial eligible cognitively normal participants age 65 and older in the National Alzheimer’s Coordinating Center Uniform Data Set to model trial sample sizes, the numbers needed to enroll to account for dropout, and the numbers needed to screen to successfully complete enrollment. We examined how enrichment strategies impacted each component of the model. Relative to trials enrolling 65 year olds, trials enriching for older (minimum 70 or 75) age required reduced sample sizes, numbers needed to enroll, and numbers needed to screen. Enriching for subjective memory complaints reduced sample sizes and numbers needed to screen more than age enrichment, but increased the number needed to screen. We conclude that AD prevention trials can enroll elderly participants with minimal impact on trial retention and that enriching for older individuals with memory complaints may afford efficient trial designs.

Keywords

Alzheimer’s disease; prevention; clinical trials

INTRODUCTION

Clinical trials continue to target earlier stages of Alzheimer’s disease (AD) because of concern that later intervention may not effectively slow progression due to established pathological burden (Sperling et al., 2011a). The earliest test of a potential intervention is through primary prevention trials that enroll volunteers with no clinical or biological sign of disease. Previous AD primary prevention trials encountered challenges related to slow enrollment, high screen failure rates, loss-to-follow-up, and fewer than expected cases of dementia (DeKosky et al., 2008, Sano et al., 2008, Meinert et al., 2009, Vellas et al., 2012), despite strategies to enrich for age (DeKosky et al., 2008), family history of disease (ADAPT Research Group et al., 2007, Sano et al., 2008), or memory complaints (Vellas et
Trial designs that incorporate single continuous outcomes of global cognitive and functional performance, rather than time-to-event designs, may alleviate some of these challenges (Aisen et al., 2011, Richard et al., 2012) and have been endorsed by regulatory agencies for trials of those at greatest risk for AD dementia (Kozauer and Katz, 2013, Center for Drug Evaluation and Research, 2013).

The Clinical Dementia Rating Scale Sum of the Boxes Score (CDR-SB) (Morris, 1993) measures within-patient clinical change assumed to represent brain disease, rather than normal aging (Morris et al., 1991), and has been proposed as a potential single primary outcome measure for use in predementia AD trials (Aisen et al., 2011, Kozauer and Katz, 2013). We used data from healthy control participants in the National Alzheimer’s Coordinating Center Uniform Data Set (NACC UDS) to model AD trials that enroll cognitively normal participants and use the CDR-SB as a single outcome. We examined how enrichment strategies will impact the rates of trial retention and screen failure. We hypothesized that using higher minimum ages of enrollment and other enrichment strategies would reduce required sample sizes but would also increase the rates of screen failure and dropout.

METHODS

Participants

The NACC UDS is a repository for longitudinal data collected from approximately 30 current or previously NIA-funded AD Centers nationwide (www.alz.washington.edu; Morris et al., 2006, Beekly et al., 2007). The UDS was initiated in 2005. These analyses examined data collected on or before December 1, 2012.

Study inclusion criteria

We examined the proportion of NACC UDS participants enrolled as cognitively normal healthy controls at baseline that was eligible for AD prevention clinical trial criteria and the criteria that most often resulted in ineligibility. To examine eligibility, we developed a set of inclusion criteria, adapted from previous AD prevention trials (DeKosky et al., 2008, Vellas et al., 2012). Participants must have been enrolled as healthy control subjects, be age 65 to 90, score above 26 on the Mini Mental Status Examination (MMSE; Folstein et al., 1975) and have a global CDR score of 0. To permit accurate examination of long-term follow-up rates, only data from participants who had a baseline visit prior to June 1, 2008 (and thus were eligible for at least three annual follow-up visits) were included.

Exclusion criteria were recent or active cardiovascular disease (e.g. heart attack, atrial fibrillation); presence of a pacemaker (since most AD trials include magnetic resonance imaging); medical conditions that might cause or contribute to cognitive impairment, including vitamin B12 deficiency, thyroid disease, alcohol or other substance abuse, Parkinson’s disease, seizures, or traumatic brain injury; history of stroke; Hachinski ischemia scale score greater than 4; and geriatric depression scale (GDS) score greater than 6. For the medical conditions, patients were not excluded if the condition was characterized as remote or inactive. For vitamin B12 and thyroid deficiency, this was assumed to separate patients with a current active condition from those with a previous diagnosis adequately treated. The use of the following concomitant medications was exclusionary: lithium, anti-Parkinsonian medications, MAO-B Inhibitors, tricyclic antidepressants and other anticholinergic drugs (including diphenhydramine), stimulants (i.e. modafinil and methylphenidate), narcotic analgesics, first generation antipsychotics, atypical antipsychotics, anticonvulsants, and approved AD therapies.
Enrichment strategies

Age—We assessed the impact of limiting trial populations to those at least age 70 or 75.

Apolipoprotein E (ApoE) ε4 carrier status—ApoE genotype is a well-described genetic risk factor for AD (Corder et al., 1993). ApoE genotyping was performed locally at NACC ADCs or at the National Cell Repository for AD, primarily using blood samples. Subjects were divided into those who did and those who did not carry at least one ε4 allele.

Education levels—Demographic collection of information as part of the NACC UDS includes the highest level of educational completion for all participants. Education may serve as a surrogate for cognitive reserve and cognitive reserve may protect against cognitive decline (Stern, 2009). We enriched trial models by excluding those assumed to have the greatest cognitive reserve, those with a maximum education level greater than 16 years.

Subjective cognitive complaint—As part of the NACC UDS the clinician is asked to record whether the participant reports a decline in memory. The accompanying instructions in the UDS Coding Guidebook state that decline refers to cognitive changes in the subject’s usual or customary memory function and that changes in behavior, motor, or other non-memory symptoms should not be considered. We used this single item to categorize participants as having a subjective cognitive complaint.

CDR-SB

The CDR is an interview-based assessment tool. The researcher separately interviews an informant and the participant and assesses the participant’s change relative to their premorbid (in this case earlier life) performance on six domains: memory; orientation, judgment and problem solving; community affairs; home and hobbies; and personal care. Each domain is scored as 0 (no dementia), 0.5 (questionable), 1.0 (mild), 2.0 (moderate), or 3 (severe dementia). Two overall scores can be derived, a global score using a standardized algorithm and a cumulative score summing the boxes. The CDR-SB is a well-described, validated, and reliable measure of change through the course of AD (Morris, 1993, Williams et al., 2009) and has been proposed as a suitable single outcome measure for AD trials in both dementia and predementia AD populations (Aisen et al., 2011, Coley et al., 2011, Cedarbaum et al., 2013, Kozauer and Katz, 2013).

Data analyses

We examined the mean decline in the CDR-SB at 36 months. Sample size estimates under an assumption of normality and known variance were calculated from an equation used frequently in the literature (Fox et al., 2000, Leung et al., 2010, Schott et al., 2010, Grill et al., 2013a):

\[ n = \left( \frac{z_{1-\beta} + z_{1-\alpha/2}}{\Delta \mu} \right)^2 \times \frac{2\sigma^2}{\Delta \mu^2} \]

Here, \( z_{1-\beta} = 0.842 \) to provide 80% power; \( z_{1-\alpha/2} = 1.96 \) to test at the 5% level; \( \Delta \mu \) is the mean change in CDR-SB score relative to baseline, multiplied by the drug effect (0.25) to reflect the estimated mean difference between placebo group change scores and drug group change scores; and \( \sigma \) is the SD of the change scores in the groups (assuming SD is the same in treatment and placebo groups). We report sample sizes per trial arm.
We calculated the retention rate after 36 months in NACC for each modeled population. Those who discontinued study participation, were lost-to-follow-up, or died during the 3-year interval were considered to have dropped out of the study. Using the specific retention rate and the calculated sample size for each population, we calculated the number needed to enroll for a trial to maintain statistical power at completion. Finally, we examined the proportion of NACC participants who met eligibility criteria for each specific trial model. Using the rates of inclusion and the number needed to enroll, we calculated the number needed to screen.

To assist in the comparison of sample size estimates, we calculated the 95% confidence intervals (CI) for the sample sizes, numbers-needed-to-enroll, and numbers-needed-to-screen. These confidence intervals were estimated by using bootstrap resampling, calculating 10,000 iterations for each scenario. Formal statistical comparisons of model outputs were not performed.

Descriptive statistics (mean, standard deviation, and percentages) were calculated for eligible trial populations. The frequency of each reason for trial ineligibility was also calculated. Groups were compared by Chi square test ($\chi^2$), and Kruskal Wallis (KW) test, as appropriate. Age comparisons were performed on the mutually exclusive age epochs (i.e. 65–69; 70–74; ≥75). All analyses were performed using SAS 9.3 (Cary, NC) and R v2.14 (http://www.R-project.org, Accessed March 1, 2012).

Human subjects protection

Each participant provided written informed consent, approved by the local Institutional Review Boards at each participating AD Center.

Results

Eligible participants

Data from 4,549 cognitively normal NACC participants were included in these analyses. Among subjects age 65 or older, 1,879 (41%) were deemed trial eligible. Among older participants, the proportion eligible was significantly lower; 39% of participants age 70 or older and 36% of those age 75 or older were eligible ($p<0.001$; Table 1). Older eligible participants were more often male, less often had a family history of AD, and were less frequently carriers of the $\varepsilon4$ allele of the ApoE genotype (Table 1). Older eligible subjects had worse scores on the MMSE but not the CDR-SB.

The reasons for trial ineligibility differed among the age groups (Table 2). Older patients were more often excluded for MMSE; the use of an FDA-approved anti-dementia medication or another excluded medication; a history of cardiovascular disease and stroke; scores on the Hachinski ischemia scale and GDS; and for a global CDR score greater than 0.

Dropout rate

Among trial eligible cognitively normal NACC participants, 36% dropped out before the 3-year time point. We did not observe an increase in the rate of dropout with age (Table 3). Dropout was lower among APOE $\varepsilon4$ carriers and those with a subjective memory complaint.

Trial modeling

The mean change on the CDR-SB over three years for cognitively normal trial eligible NACC participants age 65 or older was $0.21 \pm 0.86$ (Table 4). To adequately power a 3-year trial to demonstrate a 25% drug effect in these participants using the CDR-SB, 4,137 participants/arm would be required (Table 5). Adjusting for trial retention, 6,424...
participants/arm would need to be enrolled to maintain adequate power for a completed trial. Because only 41% of NACC cognitively normal participants met eligibility criteria (Table 6), the number needed to screen for such a trial would be 15,555 participants/arm, or just over 31,000 total volunteers.

**Enrichment strategies**

With increasing minimum age, decline measured by the CDR-SB over three years increased (Table 4), thereby reducing the number of participants needed to adequately power a trial (Table 5). Relative to the standard trial model enrolling participants age 65 or older, trials with a minimum age requirement of 70 and 75 years reduced the necessary trial sample sizes by 8% and 18%, respectively. Contrary to our hypothesis, we did not observe an increase in the dropout rate in the older populations (Table 3). Thus, the number needed to enroll was similarly reduced among the older age groups. Although the proportion of older cognitively normal participants who met trial criteria was reduced relative to younger groups, this difference was not great enough to counteract the other aspects of the trial model and the number needed to screen was also decreased in the older groups (Table 5).

Among the other enrichment strategies, limiting to those who had less than a college education did not improve the trial models (Table 5). Although carriers of the APOE ε4 genotype did not demonstrate greater decline over three years, reduced variance in this population (Table 4), resulted in a 39% smaller required sample size for this trial model, relative to a trial enrolling all eligible participants. Since the dropout rate was reduced in APOE ε4 carriers, the number needed to enroll (n=3,642/arm) was similarly reduced. In contrast, only 20% of cognitively normal NACC participants age 65 or older were APOE ε4 carriers. Thus, the number needed to screen for this trial model was 32,231/arm, an increase of 107%. Participants with a subjective memory complaint demonstrated a greater decline than the overall population on the CDR-SB over three years (Table 4) and the trial sample size model enriched for this population was reduced by 68% (Table 5). Because dropout in this group was reduced, relative to the overall population, the number needed to enroll for this model was reduced by 74%. Few NACC participants, however, presented with a memory complaint. Subsequently, the number needed to screen was 58% larger than that of the overall population.

In every model in which age was combined with another enrichment strategy, the sample size needed and the number needed to enroll were reduced, relative to the standard model accepting eligible participants age 65 or older (Table 5). These reductions ranged from a 7% reduction in the sample size for the model of minimum age of 70 years and exclusion of those with advanced education, to a 76% reduction in the number needed to enroll in a model of trial that enrolls only 75 year or old participants with a subjective memory complaint. As expected, the numbers needed to screen were increased for all models, ranging from a 72% increase in the number needed to screen for models of trials enrolling only APOE ε4 carriers who are at least 70 years old, to a 38% increase for trials that enroll only 75 year or old participants who have less than 16 years education.

**Discussion**

Studies such as this one can assist investigators in designing future predementia AD trials. This may include primary prevention trials enrolling volunteers with no biological or clinical sign of AD and secondary prevention trials of those at increased clinical (e.g. mild cognitive impairment) or biological risk for AD (see below). Previous primary (DeKosky et al., 2008, Sano et al., 2008, Meinert et al., 2009, Vellas et al., 2012) and secondary (Feldman et al., 2007) AD prevention trials have faced challenges including fewer than expected cases of AD. One strategy to overcome this challenge is to move toward continuous cognitive...
(Salmon et al., 2006) or global outcomes (Aisen 2010). We modeled predementia trials that enroll cognitively normal participants and use the CDR-SB as a single continuous outcome measure.

Our study has several strengths. We used the observed rates of longitudinal change on CDR-SB, the three-year retention rates, and the rates of eligibility of the specific populations modeled to calculate the number of participants that would be necessary to adequately power trials, the number needed to enroll (factoring in observed dropout) and the number needed to screen (factoring in screen failures) for each varying design. To our knowledge, we are the first study to model AD trials of any type using both longitudinal change scores on primary outcome measures and retention rates of those same populations.

We found that the majority of cognitively normal research participants in the NACC UDS failed to meet eligibility criteria, suggesting that timely completion of trial enrollment in AD prevention trials may face significant challenges. Reasons for exclusion included factors that can be assessed via telephone screening (such as the presence of excluded medications), as well as factors that require in-clinic assessments (such as laboratory tests or clinical outcome measures). Of note, in each age cohort, more than 20% of participants were excluded for a global CDR score greater than 0, suggesting the presence of at least some clinical abnormality. Our modeled screen failure rates may be underestimations, as an increasing proportion of the age groups examined may present microvascular changes (Kantarci et al., 2013) that may preclude participation depending on the particular trial design and intervention tested (Sperling et al., 2011b). The NACC UDS does not collect information on white matter hyperintensities or microhemorrhages in cognitively normal participants.

As expected, we found that various enrichment strategies can improve trial sample size requirements. Contrary to our hypothesis, enriching trials for elderly (at least 70 or 75 years of age) participants was not associated with increased dropout rates and, therefore, models of such trials afforded improved requirements for not only sample size equations based on mean decline, but also models that account for participant retention. Results from at least one prevention trial support this finding (Meinert and Breitner, 2008). Furthermore, even though the older group had a lower rate of eligibility compared to younger populations, a model that accounted for the number needed to screen was still reduced in the older groups.

Among the remaining enrichment strategies, enrolling those with subjective memory impairment stood out as optimal. Regardless of age enrichment, subjective complaints reduced the required sample sizes by nearly 70%, and because this group had improved retention, the models of the number needed to enroll were reduced by roughly 75% in each age-defined model. Since dementia rates were not appreciably higher in an AD prevention trial that enriched for individuals with cognitive complaints (Vellas et al., 2012), relative to trials using alternate strategies (DeKosky et al., 2008, Breitner et al., 2011), this may suggest that the use of a continuous outcome in our models was key to improved trial logistics. Indeed, our results, in line with some (Wang et al., 2004, Dufouil et al., 2005) but not all (Flicker et al., 1993, Smith et al., 1996) previous studies, suggest that individuals with cognitive complaints may be at greatest risk for immediate cognitive and functional decline. In comparison, enriching for APOE ε4 carriers reduced sample sizes by 39%–70%, depending on whether a combined strategy also enriching for age was utilized.

The numbers needed to screen for trials enrolling participants with subjective complaints were increased by 54%–60%. These models may translate poorly to practice, as recruitment strategies for such a trial could simply target those with memory concerns. The true screen failure rate for such a trial would ultimately be based on the number of volunteers with a complaint who tested abnormally on neuropsychological and diagnostic criteria (e.g. meet...
criteria for dementia or mild cognitive impairment). For example, in our sample, more than 50% of otherwise eligible participants with subjective memory complaints were excluded for a global CDR score >0 (data not shown).

This study has limitations. The NACC UDS is not a population study so it is unclear how these results will translate into actual trials. Nonetheless, the cognitively normal participants in the UDS are enrolled at academic AD Centers, as was the case for many previous primary AD prevention studies. The models of the oldest age group were based on fewer data than those for the younger groups, especially when combining enrichment strategies (Table 5). This also may limit the external validity of these results. More sophisticated measures of subjective complaint exist and are being incorporated into ongoing multicenter studies such as the AD Neuroimaging Initiative (Saykin et al., 2006). Scales using multiple questions to assess memory and other cognitive domains may provide more sensitive assessments of change from premorbid function and it is unknown how incorporation of such scales might impact these results. Finally, secondary prevention trials of those with and without cognitive impairment, incorporating biological markers of AD as inclusion criteria are ongoing or imminent (Sperling et al., 2011a). The use of AD biomarkers presents potential logistical and ethical challenges associated with participant reluctance to undergo and learn biomarker testing status (Grill et al., 2013b). Biomarkers also add significant cost. The UDS does not currently collect such biomarker data. Though it is increasingly agreed that biomarkers are predictive of risk for future impairment (Morris et al., 2009, Roe et al., 2013), the utility of using these markers as inclusion criteria in predementia trials is not yet clear (Schneider et al., 2010). Our results do not instruct how the applied strategies compare to biomarker strategies of trial enrichment.

In summary, most AD trial planning studies have used standard sample size calculations without considering the important factors of participant retention and screen failure rate. This AD prevention trial modeling study considered these variables and suggested that careful planning can afford investigators the opportunity to enrich trials for those at greatest risk for cognitive and functional decline, with no impact on trial retention and minimal impact on screen failure rates.

Acknowledgments

Dr. Grill is supported by NIA AG016570, Alzheimer’s Association NIRG 12-242511, and by the Sidell-Kagan Foundation. Ms. Monsell is supported by UO1 AG016976. Research using the NACC database is also supported by UO1 AG016976. The authors wish to thank Dr. Walter Kukull for critical review of the manuscript and the participants in the NACC UDS.

References

Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M. ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007; 68:1800–1808. [PubMed: 17460158]

Aisen PS. Pre-dementia Alzheimer’s trials: overview. The Journal of Nutrition, Health & Aging. 2010; 14:294.

Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011; 76:280–286. [PubMed: 21178097]

Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA. The National Alzheimer’s Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Disease and Associated Disorders. 2007; 21:249–258. [PubMed: 17804958]
Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimer’s & Dementia. 2011; 7:402–411.

Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, Vellas B. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials. Alzheimer’s & Dementia. 2013; 9:S45–55.

Center for Drug Evaluation and Research. Guidance for industry: Alzheimer’s disease: developing drugs for the treatment of early stage disease. Feb. 2013 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf

Coley N, Andrieu S, Jaros M, Weiner M, Cedarbaum J, Vellas B. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer’s disease trials. Alzheimer’s & Dementia. 2011; 7:602–610. e602.

Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993; 261:921–923. [PubMed: 8346443]

DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD. Ginkgo biloba for prevention of dementia: a randomized controlled trial. The Journal of the American Medical Association. 2008; 300:2253–2262.

Dufouil C, Fuhrer R, Alperovitch A. Subjective cognitive complaints and cognitive decline: consequence or predictor? The epidemiology of vascular aging study. Journal of the American Geriatrics Society. 2005; 53:616–621. [PubMed: 15817007]

Feldman HH, Ferris S, Winblad B, Sifakis N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orogogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDeX study. Lancet Neurology. 2007; 6:501–512. [PubMed: 17509485]

Flicker C, Ferris SH, Reisberg B. A longitudinal study of cognitive function in elderly persons with subjective memory complaints. Journal of the American Geriatrics Society. 1993; 41:1029–1032. [PubMed: 8409146]

Folstein MF, Folstein ME, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189–198. [PubMed: 1202204]

Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Archives of Neurology. 2000; 57:339–344. [PubMed: 10714659]

Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, Chow N, Kohannim O, Cummings JL, Thompson PM, Elashoff D. Estimating sample sizes for predementia Alzheimer’s trials based on the Alzheimer’s Disease Neuroimaging Initiative. Neurobiology of Aging. 2013a; 34:62–72. [PubMed: 22503160]

Grill JD, Karlwash J, Elashoff D, Vickrey BG. Risk disclosure and preclinical Alzheimer’s disease clinical trial enrollment. Alzheimer’s & Dementia. 2013b; 9:356–359.

Kantarci K, Gunter JL, Tosakulwong N, Weigand SD, Senjem MS, Petersen RC, Aisen PS, Jagust WJ, Weiner MW, Jack CR Jr. Focal hemosiderin deposits and beta-amyloid load in the ADNI cohort. Alzheimer’s & Dementia. 2013 epub ahead of print.

Kozauer N, Katz R. Regulatory Innovation and Drug Development for Early-Stage Alzheimer’s Disease. The New England Journal of Medicine. 2013 epub ahead of print.

Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR Jr, Weiner MW, Fox NC, Ourselin S. Robust atrophy rate measurement in Alzheimer’s disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. NeuroImage. 2010; 50:516–523. [PubMed: 20034579]
Meinert CL, Breitner JC. Chronic disease long-term drug prevention trials: lessons from the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimer’s & Dementia. 2008; 4:S7–S14.

Meinert CL, McCaffrey LD, Breitner JC. Alzheimer’s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimer’s & Dementia. 2009; 5:93–104.

Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43:2412–2414. [PubMed: 8232972]

Morris JC, McKeel DW Jr, Storandt M, Rubin EH, Price JL, Grant EA, Ball MJ, Berg L. Very mild Alzheimer’s disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology. 1991; 41:469–478. [PubMed: 2011242]

Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Archives of Neurology. 2009; 66:1469–1475. [PubMed: 20008650]

Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Disease and Associated Disorders. 2006; 20:210–216. [PubMed: 17132964]

Richard E, Andrieu S, Solomon A, Mangialasche F, Ahtiluoto S, Moll van Charante EP, Coley N, Fratiglioni L, Neely AS, Vellas B, van Gool WA, Kivipelto M. Methodological challenges in designing dementia prevention trials - the European Dementia Prevention Initiative (EDPI). Journal of the Neurological Sciences. 2012; 322:64–70. [PubMed: 22818266]

Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, Sutphen CL, Benzinger TL, Mintun MA, Holtzman DM, Morris JC. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013 epub ahead of print.

Salmon DP, Cummings JL, Jin S, Sano M, Sperling RA, Zamrini E, Petersen RC, Thal LJ, Ferris SH. ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials. Alzheimer Disease and Associated Disorders. 2006; 20:S139–146. [PubMed: 17135807]

Sano M, Jacobs D, Andrews H, Bell K, Graff-Radford N, Lucas J, Rabins P, Bolla K, Tsai WY, Cross P, Andrews K, Costa R, Xiaodong L. A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer’s disease and loss of memory in women: design and baseline characteristics. Clin Trials. 2008; 5:523–533. [PubMed: 18827045]

Saykin AJ, Wishart HA, Rabin LA, Santulli RB, Flashman LA, West JD, McHugh TL, Mamourian AC. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006; 67:834–842. [PubMed: 16966547]

Schneider LS, Kennedy RE, Cutter GR. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimer’s & Dementia. 2010; 6:367–377.

Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC. Reduced sample sizes for atrophy outcomes in Alzheimer’s disease trials: baseline adjustment. Neurobiology of Aging. 2010; 31:1452–1462. 1462 e1451–1452. [PubMed: 20620665]

Smith GE, Petersen RC, Ivnik RJ, Malec JF, Tangalos EG. Subjective memory complaints, psychological distress, and longitudinal change in objective memory performance. Psychology and Aging. 1996; 11:272–279. [PubMed: 8795055]

Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Science Translational Medicine. 2011a; 3:111cm133.

Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer’s & Dementia. 2011b; 7:367–385.

Stern Y. Cognitive reserve. Neuropsychologia. 2009; 47:2015–2028. [PubMed: 19467352]
Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurology. 2012; 11:851–859. [PubMed: 22959217]

Wang L, van Belle G, Crane PK, Kukull WA, Bowen JD, McCormick WC, Larson EB. Subjective memory deterioration and future dementia in people aged 65 and older. Journal of the American Geriatrics Society. 2004; 52:2045–2051. [PubMed: 15571540]

Williams MM, Roe CM, Morris JC. Stability of the Clinical Dementia Rating, 1979–2007. Archives of Neurology. 2009; 66:773–777. [PubMed: 19506139]
### Table 1
Demographic summaries for each group of trial-eligible participants by age.

| Characteristic                              | Age 65+ | Age 70+ | Age 75+ | P-value |
|---------------------------------------------|---------|---------|---------|---------|
| Eligible participants, n (%)                | 1879 (41%) | 1443 (39%) | 956 (36%) | <0.001 ($X^2$) |
| Mean age, years (SD)                        | 75.2 (6.5) | 77.7 (5.3) | 80.6 (4.1) | <.0001 (KW) |
| Female gender, n (%)                        | 1253 (67%) | 944 (65%) | 613 (64%) | 0.04 ($X^2$) |
| Race: White, n (%)                          | 1549 (82%) | 1191 (83%) | 804 (84%) | 0.10 ($X^2$)\textsuperscript{a,b} |
| Black, n (%)                                | 246 (13%) | 183 (13%) | 109 (11%) |         |
| Asian, n (%)                                | 33 (2%)   | 31 (2%)   | 23 (2%)   |         |
| Multiracial, n (%)                          | 46 (2%)   | 33 (2%)   | 17 (2%)   |         |
| Other or Unknown, n (%)                     | 5 (0.3%)  | 5 (0.4%)  | 3 (0.2%)  |         |
| Latino ethnicity, n (%)                     | 65 (3%)   | 51 (4%)   | 31 (3%)   | 0.67 ($X^2$)\textsuperscript{b} |
| Family history of dementia, n (%)           | 975 (52%) | 686 (48%) | 416 (44%) | <.0001 ($X^2$)\textsuperscript{b} |
| Education: No college, n (%)                | 358 (19%) | 282 (20%) | 194 (20%) | 0.37 ($X^2$)\textsuperscript{b} |
| At least some college, n (%)                | 1513 (81%) | 1156 (80%) | 758 (79%) |         |
| APOE: e4 carriers                           | 384 (20%) | 263 (18%) | 148 (15%) | <.0001 ($X^2$)\textsuperscript{b} |
| e4 non-carriers                             | 1045 (56%) | 828 (57%) | 580 (61%) |         |
| Unknown/missing                             | 450 (24%) | 352 (24%) | 228 (24%) |         |
| Subjective cognitive complaint, n (%)       | 313 (17%) | 236 (16%) | 165 (17%) | 0.35 ($X^2$) |
| Baseline MMSE                               | 29.0 (1.1) | 29.0 (1.2) | 28.9 (1.2) | <.0001 (KW) |
| Baseline CDR-SB                             | 0.01 (0.1) | 0.01 (0.1) | 0.01 (0.1) | 0.49 (KW) |

Statistical comparisons are made between the mutually exclusive age epochs.

\textsuperscript{a} For white vs. non-white race;

\textsuperscript{b} Missing or unknown values excluded from statistical testing.

*Neurobiol Aging. Author manuscript; available in PMC 2015 March 01*.
### Table 2

Reasons for trial exclusion.

| Exclusion criteria                        | Age 65+ (n, %) | Age 70+ (n, %) | Age 75+ (n, %) | P-value (X²) |
|-------------------------------------------|----------------|----------------|----------------|--------------|
| MMSE<26, n (%)                            | 330 (7%)       | 298 (8%)       | 241 (9%)       | <.0001       |
| Anti-AD medication, n (%)                 | 287 (6%)       | 273 (7%)       | 218 (8%)       | <.0001       |
| Cardiovascular disease, n (%)             | 583 (13%)      | 521 (14%)      | 426 (16%)      | <.0001       |
| Prohibited medication, n (%)              | 678 (15%)      | 620 (17%)      | 479 (18%)      | <.0001       |
| History of stroke, n (%)                  | 49 (1%)        | 48 (1%)        | 45 (2%)        | <.0001       |
| Other neurological disorder, n (%)        | 132 (3%)       | 109 (3%)       | 79 (3%)        | 0.97         |
| Vitamin B12 deficiency, n (%)             | 141 (3%)       | 116 (3%)       | 86 (3%)        | 0.90         |
| Thyroid disease, n (%)                    | 776 (17%)      | 646 (17%)      | 489 (18%)      | 0.06         |
| Alcohol or substance abuse, n (%)         | 71 (2%)        | 59 (2%)        | 40 (1%)        | 0.70         |
| Psychiatric disorder, n (%)               | 98 (2%)        | 77 (2%)        | 51 (2%)        | 0.34         |
| Hachinski ischemia scale score >4, n (%)  | 435 (10%)      | 398 (11%)      | 326 (12%)      | <.0001       |
| GDS>6, n (%)                              | 352 (8%)       | 307 (8%)       | 237 (9%)       | <.0001       |
| CDR global score>0, n (%)                 | 1015 (22%)     | 891 (24%)      | 710 (26%)      | <.0001       |

Statistical comparisons are made between the mutually exclusive age epochs.
Table 3

Dropout rate (%) at 3 years for varying enrichment strategies.

| Enrichment                       | Age criteria at baseline |
|----------------------------------|--------------------------|
|                                  | 65+ | 70+ | 75+ |
| None                             | 35.6| 36.0| 35.4|
| APOE ε4 carriers                 | 30.5| 30.4| 30.4|
| Education ≤16 years              | 36.0| 35.3| 35.1|
| Subjective cognitive complaint   | 22.4| 17.4| 14.5|
Table 4

Mean (SD) raw change in CDR-SB over three years.

|                        | Age 65+     | Age 70+     | Age 75+     |
|------------------------|-------------|-------------|-------------|
| No enrichment          | 0.21 (0.86) | 0.25 (0.97) | 0.30 (1.11) |
| APOE ε4 allele carriers | 0.19 (0.61) | 0.24 (0.67) | 0.28 (0.63) |
| Education ≤16 years    | 0.22 (0.90) | 0.26 (1.00) | 0.32 (1.16) |
| Subject cognitive complaint | 0.66 (1.52) | 0.74 (1.66) | 0.81 (1.84) |
Table 5
Prevention trial model outcomes for standard and enriched trial samples.

|                     | Age 65+         | Age 70+         | Age 75+         |
|---------------------|-----------------|-----------------|-----------------|
| **No enrichment**   |                 |                 |                 |
| N observed          | 1,211           | 924             | 618             |
| Sample size calculation, n (95% CI) | 4,137 (3,280–5,121) | 3,785 (2,961–4,725) | 3,381 (2,628–4,324) |
| Number need to enroll, n (95% CI) | 6,424 (5,094–7,952) | 5,915 (4,627–7,383) | 5,234 (4,069–6,694) |
| Number needed to screen, n (95% CI) | 15,555 (12,335–19,255) | 15,245 (11,926–19,029) | 14,744 (11,462–18,857) |
| **APOE ε4 carriers**|                 |                 |                 |
| N observed          | 267             | 183             | 103             |
| Sample size calculation, n (95% CI) | 2,531 (1,712–3,684) | 1,772 (1,267–2,984) | 1,251 (691–2,059) |
| Number need to enroll, n (95% CI) | 3,642 (2,464–5,301) | 2,546 (1,821–4,288) | 1,798 (993–2,959) |
| Number needed to screen, n (95% CI) | 32,231 (21,806–46,912) | 26,800 (19,169–45,137) | 24,631 (13,603–40,535) |
| **Education ≤16 years**|                 |                 |                 |
| N observed          | 762             | 603             | 414             |
| Sample size calculation, n (95% CI) | 4,208 (3,009–5,462) | 3,837 (2,750–5,059) | 3,314 (2,386–4,385) |
| Number need to enroll, n (95% CI) | 6,575 (4,702–8,355) | 5,931 (4,251–7,820) | 5,107 (3,677–6,757) |
| Number needed to screen, n (95% CI) | 25,000 (17,879–32,453) | 23,536 (16,870–31,032) | 21,549 (15,515–28,511) |
| **Subjective cognitive complaint**|                 |                 |                 |
| N observed          | 243             | 195             | 141             |
| Sample size calculation, n (95% CI) | 1,318 (944–1,692) | 1,251 (890–1,647) | 1,294 (898–1,742) |
| Number need to enroll, n (95% CI) | 1,699 (1,217–2,181) | 1,515 (1,078–1,994) | 1,514 (1,051–2,038) |
| Number needed to screen, n (95% CI) | 24,624 (17,638–31,609) | 24,048 (17,112–31,651) | 24,820 (17,230–33,410) |
Table 6

Eligibility rate (%) at baseline for varying enrichment strategies

| Enrichment                     | Age criteria at baseline |
|--------------------------------|--------------------------|
|                                | 65+  | 70+  | 75+  |
| None                           | 41.3 | 38.8 | 35.5 |
| APOE ε4 allele carriers        | 11.3 | 9.5  | 7.3  |
| Education ≤16 years            | 26.3 | 25.2 | 23.7 |
| Subject cognitive complaint    | 6.9  | 6.3  | 6.1  |